Desonide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Desonide: Topical corticosteroid → polyp of vocal cord
One-Sentence Summary
Desonide is a low-potency topical corticosteroid with anti-inflammatory activity, marketed in India as creams and lotions. The TxGNN model predicts it may be relevant for polyp of vocal cord, but there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyp of vocal cord |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for desonide. Based on its known drug class, it is a topical corticosteroid, and glucocorticoids generally reduce inflammation and edema. In principle, such an effect could ease inflammation in reactive laryngeal lesions.
The plausibility is weak, however. Vocal cord polyps are mainly managed with voice rest, voice therapy, or surgery. Desonide is formulated as a skin cream or lotion, which is not suited to delivery to the larynx. The score of 0.9991 is a computational output only, and no study has examined desonide for this condition.
Other polyp-type diseases also appear among the model’s outputs, but none has any trial or publication support either.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
The local data list 20 valid single-ingredient licences, and the list may be partial. Main examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 60479 | Desonate 0.05% Lotion | Bottle of 30 ml lotion | Not recorded |
| 61577 | Decare Cream | Tube of 20 gm cream | Not recorded |
| 61019 | Desoft 0.05% Cream | Tube of 10 gm cream | Not recorded |
| 61695 | Desomag Cream | Tube of 15 gm cream | Not recorded |
| 61939 | Desograce 0.05% Cream | Tube of 20 gm cream | Not recorded |
Safety Considerations
Please refer to the package insert for safety information. No label warnings, contraindications, or drug interaction data were available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications (evidence level L5). A topical skin formulation is also poorly matched to the larynx, where vocal cord polyps are normally treated by voice therapy or surgery.
To proceed, the following is needed:
- Direct preclinical or clinical evidence on desonide or corticosteroids in vocal cord polyps
- Mechanism of action data for desonide
- An assessment of whether a suitable route of delivery to the larynx exists
- Package insert warnings and contraindications from the local regulator
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.